文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

免疫调节剂通过增强抗菌免疫对抗耐多药结核

Immunomodulatory Agents Combat Multidrug-Resistant Tuberculosis by Improving Antimicrobial Immunity.
PubMed 文献 · J Infect Dis · 2021-01-01

本研究在感染不同耐药谱结核分枝杆菌分离株(n=15)的人巨噬细胞模型中,测试活性维生素D3(vitD)联合苯丁酸(PBA)与利福平或异烟肼的抗菌效果。结果显示vitD+PBA可抑制临床耐多药结核株生长,并通过诱导抗菌肽LL-37和LC3依赖性自噬增强异烟肼和利福平的胞内抑菌作用。

要点

  • vitD+PBA通过诱导LL-37和自噬增强巨噬细胞对耐多药结核的清除。
  • vitD+PBA与异烟肼联用效果相当于>125倍异烟肼单药的胞内抑菌。
  • 免疫调节剂可作为耐多药结核标准治疗的辅助策略。

核心结论

  • 免疫调节剂vitD+PBA可增强标准抗结核药物对耐多药结核的胞内杀菌效果。

研究设计与样本

  • 使用感染15株不同耐药谱结核分枝杆菌的人巨噬细胞模型,测试vitD+PBA联合利福平或异烟肼的抗菌效果。

主要发现

  • vitD+PBA抑制人巨噬细胞内临床耐多药结核株的生长。
  • vitD+PBA通过诱导LL-37和LC3依赖性自噬增强利福平和异烟肼的胞内抑菌作用。
  • 沉默LL-37表达可增加vitD+PBA处理巨噬细胞内的耐多药结核生长。
  • vitD+PBA联合异烟肼减少胞内耐多药结核生长的效果与>125倍剂量异烟肼单药相当。

关键数值与推荐

  • 基因沉默LL-37表达可增强vitD+PBA处理巨噬细胞中耐多药结核的生长。
  • vitD+PBA联合异烟肼效果相当于>125倍异烟肼单药。

临床怎么用

  • 提示vitD+PBA可能作为耐多药结核化疗的辅助免疫调节策略,尚需临床验证。

局限性

  • 研究仅基于人巨噬细胞体外模型,未涉及动物或临床研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Multidrug-resistant (MDR) tuberculosis has low treatment success rates, and new treatment strategies are needed. We explored whether treatment with active vitamin D3 (vitD) and phenylbutyrate (PBA) could improve conventional chemotherapy by enhancing immune-mediated eradication of Mycobacterium tuberculosis. METHODS: A clinically relevant model was used consisting of human macrophages infected with M. tuberculosis isolates (n = 15) with different antibiotic resistance profiles. The antimicrobial effect of vitD+PBA, was tested together with rifampicin or isoniazid. Methods included colony-forming units (intracellular bacterial growth), messenger RNA expression analyses (LL-37, β-defensin, nitric oxide synthase, and dual oxidase 2), RNA interference (LL-37-silencing in primary macrophages), and Western blot analysis and confocal microscopy (LL-37 and LC3 protein expression). RESULTS: VitD+PBA inhibited growth of clinical MDR tuberculosis strains in human macrophages and strengthened intracellular growth inhibition of rifampicin and isoniazid via induction of the antimicrobial peptide LL-37 and LC3-dependent autophagy. Gene silencing of LL-37 expression enhanced MDR tuberculosis growth in vitD+PBA-treated macrophages. The combination of vitD+PBA and isoniazid were as effective in reducing intracellular MDR tuberculosis growth as a >125-fold higher dose of isoniazid alone, suggesting potent additive effects of vitD+PBA with isoniazid. CONCLUSIONS: Immunomodulatory agents that trigger multiple immune pathways can strengthen standard MDR tuberculosis treatment and contribute to next-generation individualized treatment options for patients with difficult-to-treat pulmonary tuberculosis.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Rao Muvva J, Ahmed S, Rekha RS, et al. Immunomodulatory Agents Combat Multidrug-Resistant Tuberculosis by Improving Antimicrobial Immunity. J Infect Dis. 2021. PMID: 33606878. doi:10.1093/infdis/jiab100

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。